Invention Grant
- Patent Title: Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
-
Application No.: US17560006Application Date: 2021-12-22
-
Publication No.: US11548952B2Publication Date: 2023-01-10
- Inventor: Brian Elliott , Tahamtan Ahmadi
- Applicant: GENMAB A/S
- Applicant Address: DK Copenhagen V
- Assignee: GENMAB A/S
- Current Assignee: GENMAB A/S
- Current Assignee Address: DK Copenhagen V
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Christopher L. Frank
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K31/555 ; A61K31/573 ; A61K31/7072
Abstract:
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
Public/Granted literature
Information query
